First humans receive experimental drug in early safety trial
NCT ID NCT07136103
Summary
This is the first study testing the experimental drug ABBV-277 in humans. Researchers will give single doses to 40 healthy volunteers to check for safety and see how the body processes the drug. The main goal is to understand side effects and how long the drug stays in the bloodstream before testing it in people with medical conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 265681
RECRUITINGGrayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.